6297-22-9

Basic information

• Product Name: Methyl 4-ketocyclohexanecarboxylate
• Synonyms: METHYL 4-KETOCYCLOHEXANECARBOXYLATE;4-OXO-CYCLOHEXANECARBOXYLIC ACID METHYL ESTER;4-CYCLOHEXANE CARBOXYLIC ACID METHYL ESTER;Cyclohexanecarboxylic acid, 4-oxo-, methyl ester;methyl 4-oxocyclohexancarboxylate;4-Oxocyclohexane-1-carboxylic acid methyl ester;Methyl cyclohexanone-4-carboxylate;4-(Methoxycarbonyl)cyclohexanone
• CAS NO: 6297-22-9
• Molecular Formula: C₈H₁₂O₃
• Molecular Weight: 156.18
• Product Categories: Drug Intermediates;Miscellaneous Reagents;Intermediates
• Mol File: 6297-22-9.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 230.8 °C at 760 mmHg
• Flash Point: 94.8 °C
• Appearance: /
• Density: 1.111 g/cm³
• Vapor Pressure: 0.0646mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: Methyl 4-ketocyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-ketocyclohexanecarboxylate(6297-22-9)
• EPA Substance Registry System: Methyl 4-ketocyclohexanecarboxylate(6297-22-9)

Safety Data

• Hazardous Substances Data: 6297-22-9(Hazardous Substances Data)

Usage

Uses

Methyl 4-Oxocyclohexanecarboxylate is an intermediate for preparation of imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for treatment of sleep disorders.

InChI:InChI=1/C8H12O3/c1-11-8(10)6-2-4-7(9)5-3-6/h6H,2-5H2,1H3

Upstream product

• 38053-91-7 2-trimethylsilyloxy-1,3-butadiene 
• 292638-85-8 acrylic acid methyl ester 
• 67-56-1 methanol 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 4630-82-4 methyl cyclohexylcarboxylate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 
• 108-95-2 phenol 
• 6940-58-5 pentane-1,3,5-tricarboxylic acid 
• 99-96-7 4-hydroxy-benzoic acid 
• 108384-35-6 methyl 3-oxocyclopent-1-enecarboxylate 
• 172908-33-7 methyl 4-hydroxybicyclo<3.1.0>hexane-1-carboxylate 
• 162086-59-1 3-hydroxy-cyclopentene-1-carboxylic acid methyl ester 
• 25662-28-6 1-(carboxymethoxy)cyclopentadiene 

Downstream Products

• 84484-24-2 4-(4-n-Pentyl-1-piperidyl)-3-cyclohexen-1-carbosaeure-methylester 
• 94593-53-0 estere metilico dell'acido cis 4-<4-(2-etossicarboniletil)fenilammino>cicloesancarbonico 
• 59498-98-5 1-Methyl-2-oxabicyclo[2.2.2]octan-3-one 
• 85977-95-3 4t-hydroxy-4c-methyl-cyclohexane-r-carboxylic acid methyl ester 
• 85977-96-4 4c-hydroxy-4t-methyl-cyclohexane-r-carboxylic acid methyl ester 
• 59498-98-5 1-Methyl-2-oxa-bicyclo[2.2.2]octan-3-one 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 129868-39-9 methyl 9-benzyl-1,2,3,4-tetrahydro-8-methylcarbazole-3-carboxylate 
• 71092-50-7 methyl 4-methylenecyclohexane carboxylate 
• 186292-98-8 4-(1H-imidazol-5-yl)cyclohexanone 
• 869501-08-6 4-(4-hydroxycyclohexyl)imidazole-1-carboxylic acid tert-butyl ester 
• 869501-07-5 4-(4-oxocyclohexyl)imidazole-1-carboxylic acid tert-butyl ester 
• 869501-15-5 cis-4-(4-tert-butoxycarbonylaminocyclohexyl)imidazole-1-carboxylic acid tert-butyl ester 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 

Relevant articles and documents

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

BICYCLIC HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Bicyclic heteroaryl derivatives of Formula 1, and pharmaceutically acceptable salts, isomers, hydrates and solvates thereof can selectively and effectively inhibit DGAT1, and thus can be useful as medicines for effectively treating dangerous diseases such as obesity, type 2 diabetes, abnormal lipidemia, metabolic syndrome (syndrome X) and the like, which are caused by DGAT1, with no adverse side effects.

Combined effects on selectivity in Fe-catalyzed methylene oxidation

Methylene C-H bonds are among the most difficult chemical bonds to selectively functionalize because of their abundance in organic structures and inertness to most chemical reagents. Their selective oxidations in biosynthetic pathways underscore the power of such reactions for streamlining the synthesis of molecules with complex oxygenation patterns. We report that an iron catalyst can achieve methylene C-H bond oxidations in diverse natural-product settings with predictable and high chemo-, site-, and even diastereoselectivities. Electronic, steric, and stereoelectronic factors, which individually promote selectivity with this catalyst, are demonstrated to be powerful control elements when operating in combination in complex molecules. This small-molecule catalyst displays site selectivities complementary to those attained through enzymatic catalysis.